In pancreatic cancer, K-RAS mutations usually develop in the early phase of carcinogenesis and patients with mutated K-RAS have significantly less overall survival compared to patients with wild type K-RAS. This evidence concerns the gene KRAS and familial pancreatic carcinoma.